Complaints Outcomes

Search

Search Results

Search Again
Pharmacist Registrant 31 (Aug 22, 2017)

The Inquiry Committee has reinstated Pharmacist Registrant’s registration which had previously been suspended for an indefinite period on March 20, 2017. Pursuant to Section 36(1) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings. The undertakings include, but are not limited to: 

  1. The Registrant will adhere to his routine medical monitoring program with the institution currently involved in his case and remain on the monitoring program for three years;

  2. The Registrant will not work alone in a pharmacy, and will, at all times, have another pharmacist or pharmacy technician/assistant/staff on site at all times;

  3. The Registrant will not have any access whatsoever, on or off-duty, to the narcotic safe in any pharmacy;

  4. The Registrant will not be involved in any way with ordering narcotic medications, except for signing off on the necessary paperwork in the presence of a witnessing pharmacy staff member for the purposes of receiving and stocking such narcotics;

  5. The Registrant will not dispense his own medications;

  6. The Registrant shall disclose to the pharmacy manager/or employer the limits and conditions on his license pursuant to the agreement prior to the commencement of new employment at any pharmacy;

  7. The Registrant will ensure that the pharmacy manager and/or employer with whom the Registrant secures employment submits a written statement to the College declaring their awareness of the Registrant’s medical condition and the agreement;

  8. The Registrant will notify the College, in writing or via e-mail, of his places of employment as a pharmacist and report any changes to the location of his employment within 48 hours of such change. A reportable change to the Registrant’s place of employment contemplates both commencement and termination of employment;

  9. The Registrant will be restricted from acting in the following roles in his practice

    • Be a manager of a pharmacy;
    • Be a director of a corporation that owns a pharmacy; and
    • Act as a preceptor.

     

The Agreement will remain in place until such time as the Registrant’s physician states otherwise. The name of the registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the registrant. The Inquiry Committee is satisfied that the undertakings will protect the public.


March 20, 2017
(AugUst 22, 2017 – Registration reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an agreement by consent with the pharmacist registrant to voluntarily suspend registration as a pharmacist effective March 20, 2017. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to section 39.3(4) of the Health Professions Act.

Yan, Cheryl Qian (Aug 10, 2017)

The Inquiry Committee has deemed Cheryl Qian Yan eligible for reinstatement of her registration, as she has completed and passed the Canadian Pharmacy Practice Programme pursuant to the terms of the Agreement reached on February 24, 2015.

Pursuant to s. 36(1) of the Health Professions Act, the Inquiry Committee has reached a revised Agreement with Ms. Yan, whereby after the reinstatement of her registration, for a specified period of time she must abide by certain limits and conditions on her practice, and she must disclose these limits and conditions to future employers. These limits and conditions include (but are not limited to):

  • Working under direct supervision of a BC pharmacist in good standing;
  • Not working alone;
  • Not being a supervisor, manager, and/or preceptor;
  • Informing employers and the College in writing regarding any medication-related incidents and/or errors that she is involved in; and
  • Notifying the College in writing regarding any changes in employment.

The Inquiry Committee considers these actions necessary to protect the public.


February 24, 2017
(August 10, 2017 – Registration reinstated)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with Ms. Cheryl Qian Yan where she has voluntarily suspended her pharmacy licence until she has completed and passed the Canadian Pharmacy Practice Programme, and then she will be subject to placing limits and/or conditions on her practice as follows depending on the setting:

  1. If a Hospital Pharmacy or Affiliated Hospital setting:

     

    1. Ms. Yan must work under the direct supervision of a BC licensed pharmacist for a period to three (3) months full time equivalent; where with the current contract, a full time week is 37.5 hours with 7.5 hour work days; and

       

    2. Ms. Yan must not work in a hospital pharmacy or an affiliated pharmacy setting as a pharmacist in a sole practitioner capacity. This means that Ms. Yan must not supervise anyone, direct work, be a manager or a preceptor or pharmacist in charge, for a period to three (3) months full time equivalent; where with the current contract, a full time week is 37.5 hours with 7.5 hour work days.

     

  2. If a Community Pharmacy setting:

     

    1. Ms. Yan will be restricted to process no more than sixty (60) prescriptions daily, within an eight (8) hour shift for a period equivalent to six (6) months full time;

       

    2. Ms. Yan must work under the direct supervision of a BC licensed pharmacist for a period equivalent to three (3) months full time, based on 8 hours per day / 40 hours per week or a total of 480 hours;

       

    3. Ms. Yan must not work in a community pharmacy as a pharmacist in a sole practitioner capacity. This means that Ms. Yan must not supervise anyone, direct work, be a manager or a preceptor or pharmacist in charge, for a period equivalent to three (3) months full time, based on 8 hours per day /40 hours per week or a total of 480 hours; and

       

    4. Ms. Yan will be subject to a practice audit in a community pharmacy of which she must complete and pass during the above six (6) months period mentioned in the above paragraphs 2 (b) and 2 (c).

The Inquiry Committee considers these actions necessary to protect the public.

Pharmacist Registrant 26 (Jun 4, 2017)

The Inquiry Committee, pursuant to Section 36(1) of the Health Professions Act, has reached a new revised Agreement with the pharmacist registrant whereby the registrant consented to undertakings that include, but are not limited to:

  1. Complying with all terms of the registrant’s monitoring program for a minimum of three additional years;

  2. Continuing counselling for one year from the date after he had returned to work;

  3. Informing all managers and employers with whom registrant gains employment of registrant’s medical condition and the limits and conditions on registrant’s registration pursuant to the Agreement;

  4. Ensuring that all managers and employers with whom registrant gains employment submits a written statement to the College declaring their awareness of Registrant’s medical condition and the agreement, and how they will accommodate and supervise registrant working in pharmacy;

  5. Working in a pharmacy where narcotic/controlled substances and Z-group drugs are counted and reconciled on a weekly basis;

  6. Working a maximum number of hours and shifts per week for the first three months after signing the Agreement;

  7. Informing his pharmacy manager of all wastages and breakages of narcotic, controlled, opioid and sedative drugs that he has to dispose of or deal with;

  8. Not conducting drug counts and/or conduct medication reconciliation for any narcotic/controlled substances or Z-group drugs;

  9. The registrant will be restricted from acting in the following roles:

    1. an owner or manager of a pharmacy;
    2. a director of a corporation that owns a pharmacy; and
    3. a preceptor;

     

  10. The registrant will notify the College regarding any of the following changes:

    1. changes in places of employment as a pharmacist;
    2. changes in residential address and phone number; and
    3. changes in medical provider;

     

The Agreement will remain in place for a minimum of four years or until such time as the registrant’s physician states otherwise. The name of the registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the registrant. The Inquiry Committee is satisfied that the undertakings will protect the public.


January 3, 2017
(June 4, 2017 – Limits and conditions updated)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended indefinitely on May 16, 2016. Pursuant to Section 36 of the Health Professions Act, the Inquiry Committee has reached an agreement with the pharmacist registrant whereby the registrant consented to undertakings involving regular monitoring for fitness to practice pharmacy. The undertakings include, but are not limited to:

  1. That the registrant will comply with all terms of registrant’s monitoring program with the company currently involved in registrant’s care and remain on this program for a minimum of three (3) years from the day registrant returns to active employment as a pharmacist;

  2. That registrant will continue counselling for one (1) year after registrant returns to work;

  3. That registrant will inform all managers and employers with whom registrant gains employment of registrant’s medical condition and the limits and conditions on registrant’s registration pursuant to this agreement;

  4. That registrant will ensure that all managers and employers with whom registrant gains employment submit a written statement to the College within 48 hours of securing employment, declaring their awareness of registrant’s medical condition and the agreement, how they will accommodate and supervise registrant working in the pharmacy, and that they will submit a weekly narcotic count for a minimum of three (3) months to the College or advise the College if any narcotic count concerns arise;

  5. That after returning to work in a pharmacy setting, registrant will provide work sign-in sheets on a monthly basis;

  6. That registrant will not work alone after returning to work in a pharmacy setting and that there must be overlapping shifts of at least one registrant during registrant’s work shift for a minimum of the first six (6) months that registrant returns to work;

  7. That after returning to work in a pharmacy setting, registrant will not be allowed to dispense narcotics;

  8. That after returning to work in a pharmacy setting, registrant will not handle or physically prepare prescriptions for narcotic, controlled, opioid and sedative drugs, including but not limited to Benzodiazepine, Dextroamphetamine and testosterone products and any Z-Group drugs;

  9. That after returning to work in a pharmacy setting, for the first six (6) months, registrant will not be allowed to dispense Controlled Substances ie. Benzodiazepine, Dextroamphetamine and testosterone products and any Z-Group drugs (which are not considered Controlled Substances);

  10. That after returning to work in a pharmacy setting, registrant will not be allowed to do narcotic or controlled substances or Z-Group drug counts;

  11. That after returning to work in a pharmacy setting, registrant will not dispose or deal with wastage or breakage of or otherwise handle any narcotic, controlled, opioid and sedative drugs, including but not limited to Benzodiazepine, Dextroamphetamine and testosterone products and any Z-Group drugs;

  12. That registrant will not have access to the narcotic-safe or physically process and/or otherwise prepare any prescriptions that require access to the narcotic safe;

  13. That registrant will not be involved in any way with ordering supplies of narcotic medications;

  14. That registrant will be restricted from acting in the following roles in registrant’s practice: 

    1. an owner or manager of a pharmacy;
    2. a director of a corporation that owns a pharmacy; and
    3. a preceptor;

     

  15. That registrant will be restricted from acting in the following roles in registrant’s practice: 

    1. all changes in places of employment as a pharmacist;
    2. all changes in residential address and phone number; and
    3. all changes in medical provider;

The agreement will remain in place for a minimum of five years from the date of execution of the agreement. The registrant will be assessed by the treating physician after six (6) months upon return to active employment to determine whether or not any of the above limits or conditions should be removed. The name of the registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public.


May 16, 2016
(January 3, 2017 – Registration Reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an agreement with the pharmacist registrant to voluntarily suspend the registration as a pharmacist effective May 16, 2016. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to section 39.3(4) of the Health Professions Act.

Ratansi, Elishah (May 13, 2017)

Elishah Ratansi has satisfied terms of an agreement reached with the Inquiry Committee on July 6, 2015. Limits and conditions on the Elishah Ratansi’s registration as a pharmacist have now been removed.


August 12, 2016
(May 13, 2017 – Limits and conditions removed)

The Registration Committee has reinstated Ms. Ratansi’s registration as a Full/Active Pharmacist, effective August 12, 2016. Pursuant to a Consent Agreement signed on July 6, 2015, Ms. Ratansi agrees to the following limits and conditions on her practice, effective August 12, 2016:

  1. Prohibition from acting as a director for 9 months upon return to practice as a Full/Active Pharmacist; and
  2. Prohibition from acting as a pharmacy manager for 9 months upon return to practice as a Full/Active Pharmacist.

July 6, 2015
(August 12, 2016 – Registration reinstated)

Pursuant to section 36 of the Health Professions Act, the Inquiry Committee has reached a Consent Agreement with Ms. Elishah Ratansi, effective July 6, 2015. This was the result of investigations conducted on a pharmacy under the management of Ms. Ratansi where several practice violations were allegedly found.  Also in the course of her employment as a pharmacist at the pharmacy in question, an illegal delivery scheme for transporting controlled substances was allegedly implemented by the management and pharmacy staff.  In light of the Inquiry Committee’s investigation and findings, Ms. Ratansi voluntarily placed her licence on non-practising status since January 1, 2015.  She agreed to the following terms in the Consent Agreement, among others:

  1. Suspension of registration as a pharmacist for six consecutive months, effective January 1, 2015. 
  2. Prohibition from acting as a director for 9 months upon return to practice as a Full/Active Pharmacist,
  3. Prohibition from acting as a pharmacy manager for 9 months upon return to practice as a Full/Active Pharmacist,
  4. Notification about this suspension will be published on the College website, pursuant to s. 39.3 of the Health Professions Act.

In the same Consent Agreement, Ms. Ratansi also agreed that she will not repeat the alleged conduct and to thoroughly review the legislation of which she was in breach.

Lam, Alexis Vanessa (May 9, 2017)

The Inquiry Committee, pursuant to section 35(1)(a) of the Health Professions Act, R.S.B.C. 1996, c. 183, for the purposes of public protection, has imposed limits and conditions on the practice of registrant Alexis Vanessa Lam, pending completion of an investigation of her pharmacy practice. Until further notice, Ms. Lam has the following limits and conditions on her practice:

  1. Effective May 9, 2017, she will be restricted from doing the following in relation to narcotic and controlled drugs and substances:
    1. Placing and receiving orders; and
    2. Signing wholesaler/manufacturer invoices confirming receipt of orders, or have any sort of signing authority relating to such orders.

Ms. Lam has not demonstrated that she has fulfilled her responsibility as a registrant to take reasonable steps to protect narcotic and controlled drugs against loss in or from the pharmacy where she works. In addition, she has not kept accurate records regarding all purchases and sales of narcotic and controlled drugs. This has enabled a large quantity of narcotic and controlled drugs at the pharmacy to be unaccounted for, causing potential harm to the public.

Lam, Miguel Angel (May 9, 2017)

The Inquiry Committee, pursuant to section 35(1)(a) of the Health Professions Act, R.S.B.C. 1996, c. 183, for the purposes of public protection, has imposed limits and conditions on the practice of registrant Miguel Angel Lam, pending completion of an investigation of his pharmacy practice. Until further notice, Mr. Lam has the following limits and conditions on his practice:

  1. Effective May 23, 2017, he will be restricted from acting as a manager of any pharmacy. 
  2. Effective May 9, 2017, he will be restricted from doing the following in relation to narcotic and controlled drugs and substances:
    1. Placing and receiving orders; and
    2. Signing wholesaler/manufacturer invoices confirming receipt of orders, or have any sort of signing authority relating to such orders.

As the pharmacy manager of a pharmacy, Mr. Lam has not been fulfilling his responsibilities to operate a pharmacy that meets legislative and practice standards. He has not kept accurate records regarding all purchases and sales of narcotic and controlled drugs. He has not established and/or enforced policies and procedures for inventory management and security and storage of narcotic and controlled drugs, enabling a large quantity of narcotic and controlled drugs at the pharmacy to be unaccounted for, causing potential harm to the public.

Pharmacist Registrant 30 (May 1, 2017)

The Inquiry Committee, pursuant to Section 36 of the Health Profession Act, has reached a new revised agreement with the pharmacist registrant, whereby the registrant consented to undertakings that include, but are not limited to:

  1. Complying with any and all treatment plans as recommended by his medical providers, including but not limited to the following:

    1. Regular and consistent attendance to his meetings with his mental health team; and
    2. Adherence to his medication regimen;

  2. Voluntarily stop working as a pharmacist and self-report to the College in the event that his medical condition may hinder his performance and/or fitness to practice as a pharmacist;

The name of the registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public.


February 8, 2017
(May 1, 2017 - Limits and Conditions Revised)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on December 23, 2016. Pursuant to Section 36 of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the registrant consented to undertakings involving regular monitoring for fitness to practice pharmacy. The undertakings include, but are not limited to:

  1. Complying with any and all treatment plans as recommended by his medical providers, including but not limited to the following:

    1. Regular and consistent attendance to his meetings with his mental health team; and
    2. Adherence to his medication regimen;

  2. That after returning to work in pharmacy setting, on every shift of employment at any pharmacy, the registrant will work alongside another pharmacist in good standing at all times;

     

  3. That prior to the commencement of new employment at any pharmacy, the registrant shall disclose to the pharmacy manager the limits and conditions of this Consent Agreement and ensure that arrangements are made in the pharmacy operations to accommodate the said limits and conditions:

    1. The registrant must ensure that the pharmacy manager and/or employer with whom the registrant secures employment submits a written statement to the College declaring:

      1. their awareness of the limits and conditions in; and
      2. their obligation to contact the College if they have questions or concerns about the registrant’s practice. This statement must be received within 48 hours of any change of employment and/or 48 hours of any change in pharmacy manager/employer.

    2. The registrant must inform a Complaints Officer in writing or via email of his places of employment as a pharmacist and report any changes of the location of his employment within 72 hours of such change.

December 23, 2016
(February 8, 2017 – Registration reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an agreement with the pharmacist registrant to suspend his registration as a pharmacist, effective December 23, 2016. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld, pursuant to s. 39.3(4) of the Health Professions Act.

Pharmacist Registrant 21 (May 1, 2017)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on July 27, 2016. Pursuant to Section 36 of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings involving regular monitoring for fitness to practice pharmacy. The undertakings include, but are not limited to:

  1. Strictly adhering to his routine medical monitoring program with the institution currently involved in his care and remaining on the monitoring program for a period of 12 months;

  2. Informing all managers and employers with whom Registrant gains employment of Registrant’s medical condition and the limits and conditions on Registrant’s registration pursuant to the agreement;

  3. Ensuring that all managers and employers with whom Registrant gains employment submits a written statement to the College declaring their awareness of Registrant’s medical condition and the agreement, and how they will accommodate and supervise Registrant working in pharmacy;

  4. Registrant will not work alone in a pharmacy setting, meaning that Registrant must never be the sole pharmacist in attendance at any time and that there must be another pharmacist or pharmacy assistant or pharmacy staff working with Registrant at all times;

  5. Registrant will not have access to narcotic-safe or physically process and/or otherwise prepare any prescriptions that require access to the narcotic safe;

  6. Registrant will not be involved in any way with ordering supplies of narcotic medications;

  7. The Registrant will not process and/or otherwise prepare any prescriptions that require access to the narcotic safe. In dispensing such prescriptions, the Registrant will only be involved in the intake, final check and pharmacist/patient counseling in accordance with the HPA Bylaws;

  8. The Registrant will be restricted from acting in the following roles in Registrant’s practice:

    1. an owner or manager of a pharmacy;
    2. a director of a corporation that owns a pharmacy; and
    3. a preceptor;

     

  9. The Registrant will notify the College, in writing or via e-mail, of:

    1. all changes in his places of employment as a pharmacist
    2. all changes in residential address and phone number; and
    3. all changes in medical provider.

The Agreement will remain in place for a minimum of 12 months from the date of execution of the Agreement, following which the Registrant may submit information or documentation, including independent medical assessments, to support removing any or all of the above limits and conditions. The name of the Registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public.


July 27, 2016
(May 1, 2017 – Registration Reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an agreement with the pharmacist registrant to suspend his registration as a pharmacist, effective July 27, 2016. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld, pursuant to s. 39.3(4) of the Health Professions Act.


February 27, 2015
(July 27, 2016 – Registration Suspended)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on July 23, 2014. Pursuant to Section 36 of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings involving regular monitoring for fitness to practice pharmacy. The undertakings include, but are not limited to:

  1. Strictly adhering to his routine medical monitoring program with the institution currently involved in his care and remaining on the monitoring program for a period of 3 years;

  2. Informing all managers and employers with whom Registrant gains employment of Registrant’s medical condition and the limits and conditions on Registrant’s registration pursuant to the agreement;

  3. Ensuring that all managers and employers with whom Registrant gains employment submits a written statement to the College declaring their awareness of Registrant’s medical condition and the agreement, and how they will accommodate and supervise Registrant working in pharmacy;

  4. Registrant will not work alone in a pharmacy setting, meaning that Registrant must never be the sole pharmacist in attendance at any time and that there must be another pharmacist or pharmacy assistant or pharmacy staff working with Registrant at all times;

  5. Registrant will not have access to narcotic-safe or physically process and/or otherwise prepare any prescriptions that require access to the narcotic safe;

  6. Registrant will not be involved in any way with ordering supplies of narcotic medications;

  7. The Registrant will not process and/or otherwise prepare any prescriptions that require access to the narcotic safe. In dispensing such prescriptions, the Registrant will only be involved in the intake, final check and pharmacist/patient counseling in accordance with the HPA Bylaws;

  8. The Registrant will be restricted from acting in the following roles in Registrant’s practice:

    1. an owner or manager of a pharmacy;
    2. a director of a corporation that owns a pharmacy; and
    3. a preceptor;

  9. The Registrant will notify the College, in writing or via e-mail, of:

    1. all changes in his places of employment as a pharmacist
    2. all changes in residential address and phone number; and
    3. all changes in medical provider.

The agreement will remain in place for a minimum of three years from the date of execution of the Agreement, following which the Registrant will be assessed by a physician to determine whether or not continuation of monitoring is necessary. The name of the Registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public.


JULY 23, 2014
(FEBRUARY 27, 2015 – REGISTRATION REINSTATED)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an agreement with the pharmacist registrant to suspend his registration as a pharmacist, effective July 23, 2014. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld, pursuant to s. 39.3(4) of the Health Professions Act.

Drapeau , Tyler Joshua (Apr 20, 2017)

Pursuant to section 36(1) of the Health Professions Act, the Inquiry Committee of the College of Pharmacists of British Columbia (the “College”) reached a consent agreement with Tyler Joshua Drapeau (the “Registrant”) to suspend his registration as a pharmacist for a period of six months, from April 20, 2017 to October 20, 2017.

After an investigation, the Registrant admitted to practicing outside of his scope by prescribing and dispensing multiple medications to himself and others without a valid prescription. The Registrant prescribed medication to himself over 30 times without any prescription from a physician and inappropriately dispensed medications to himself on various other occasions. In relation to prescribing medications to others, the Registrant prescribed and dispensed azithromycin 26 times without a valid prescription, atavaquone proguanil two times without a valid prescription and doxycycline without a valid prescription. The Registrant listed the wrong prescriber on a prescription and conducted improper adaptations and emergency refills, each not in compliance with the Professional Practice Policies.

The Inquiry Committee determined that the Registrant breached the Code of Ethics – Detailed, Standard 1(b) which states that registrants practice only within the scope of their education, training and competence, Further, the Code of Ethics – Conflict of Interests Standards, Standard 2(e) very narrowly defines that registrants may only dispense medications to themselves in an emergency situation or when another registrant is not readily available.

The Inquiry Committee determined that the Registrant acted outside of scope, that he was not trained to prescribe any of the medications at issue, and that pharmacists in British Columbia do not have authority under legislation or the Code of Ethics to prescribe to themselves.

The Inquiry Committee determined that the Registrant engaged in professional misconduct and unethical conduct in relation to the unauthorized prescribing and dispensing practices, taking into account the gravity of the contraventions listed above and that the volume of practice deficiencies constituted a serious matter.

Prior to reinstatement, the Registrant must:

  • Appear before a panel of the Inquiry Committee for a verbal reprimand;
  • Successfully complete and pass the College Jurisprudence Exam;
  • Submit a fine of $5,000;
  • Thoroughly review the relevant legislation and sign a declaration acknowledging his understanding and rigid compliance with those legislative requirements.

The Registrant may not act as a pharmacy manager for a period of three years following reinstatement.

A letter of reprimand will be permanently placed on the College register and the College may disclose its contents in response to inquiries regarding the status of the Registrant’s registration. The Inquiry Committee considers this Agreement necessary to protect the public.

Pharmacist Registrant 32 (Mar 24, 2017)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with pharmacist registrant to suspend the registrant’s registration as a pharmacist effective March 24, 2017. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The registrant's name has been withheld, pursuant to 39.3(4) of the Health Professions Act.

Pages